Clinical trials: Blood-Borne Infections
HIV Infections
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
- Trial name
- NCT00002308
- Testing
- Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen after switching their boosted PI to…
- Trial name
- NCT02097108
- Testing
- Raltegravir
- Where
- 3 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Hepatitis C Virus
TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435
The purpose of this study is to compare the levels of TMC435 in the blood circulation after intake of 2 tablet formulations with the level of TMC435 in the blood circulation after intake of a capsule formulation.
- Trial name
- NCT01022125
- Testing
- TMC435
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
This study is a two-period, double-blind study in healthy adult female subjects. Each subject will participate in an oral contraceptive Run-in period prior to the treatment periods.
- Trial name
- NCT01195974
- Testing
- YASMIN, GSK2248761
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Multi-Antiviral Resistance
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV…
- Trial name
- PROMISE-US (NCT05388474)
- Testing
- No ibalizumab or Pre-ibalizumab treatment, On ibalizumab treatment
- Where
- 36 sites in United States
- Volunteers
- 168 people
- Sponsor
- Theratechnologies
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01502397
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- The University of Hong Kong
HIV Infections
Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum
This study will evaluate the pharmacokinetic disposition of raltegravir in pregnant HIV-1 infected women. These results will be compared to pharmacokinetic data obtained following pregnancy as well as to studies previously…
- Trial name
- NCT00689910
- Where
- 4 sites in United States
- Sponsor
- University of California, San Francisco
HIV Infections
Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS
Correlation between intestinal parasites and serum level of eosinophils and IgE in individuals with HIV or aids attended at clinical hospital of the Botucatu Medical School-UNESP
- Trial name
- NCT00546689
- Volunteers
- 30 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Chronic Hepatitis C Virus
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
- Trial name
- NCT01740791
- Testing
- Velpatasvir
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
HIV/AIDS
The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls
The study will use focus group methodology in the formative evaluation phase. Focus group methodology provides a rich source of data and understanding of phenomena by allowing the researcher to examine the interaction among…
- Trial name
- NCT05014074
- Testing
- Theater/Pilot Testing
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Yale University
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
This study seeks to evaluate the efficacy and safety of ABT-493/ABT-530 in participants with Genotype 1 hepatitis C virus infection without cirrhosis
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV
- Trial name
- NCT02604017
- Testing
- ABT-493/ABT-530
- Volunteers
- 703 people
- Sponsor
- AbbVie
Cytomegalovirus Infections, HIV Infections
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109; formerly SDZ 89-109) when…
- Trial name
- NCT00002268
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz
Human Immunodeficiency Virus
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
A randomized control trial to test the effectiveness of a structured online support group, SMART (Social Media to improve ART Retention in Treatment) Connections, to improve retention in HIV care services among youth living with…
- Trial name
- Y-SMART (NCT03516318)
- Testing
- SMART Connections
- Where
- Nigeria
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- FHI 360
Chronic Hepatitis C, Chronic Liver Disease
Long Term Follow-up of Hepatitis C Cured Patients
Objectives: The general objective of the present project is to gain a better understanding of disease outcome in cACLD patients treated with the new oral DAA.
- Conditions
- Chronic Hepatitis C, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT03246048
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatitis C
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients
Hepatitis C infection is a major public health problem with nearly 175 million infected individuals worldwide. Although cure is possible, only 20-40% of patients spontaneously resolve infection and 40-80% of chronically infected…
- Trial name
- NCT01567540
- Testing
- Sitagliptin
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Diphtheria, Tetanus
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722) and booster vaccination in Study A3L27 (NCT01444781).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01983540
- Testing
- DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3.
- Trial name
- NCT00000991
- Testing
- Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone
- Where
- 21 sites in United States, Tanzania
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV Infections
T-cell Responses to Concurrent HIV and Herpesvirus Infections
This is a research study in which we are trying to discover new information about how HIV and herpes viruses interact with the immune system.
- Trial name
- NCT03996018
- Testing
- T-cell lymphocyte responses
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Hepatitis C, People Who Inject Drugs
Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (IC).
- Trial name
- NCT05895448
- Testing
- velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Center For Hepatitis C, Atlanta, GA
HIV Infections
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1.
- Trial name
- HIVGP-BCG (NCT07182838)
- Testing
- HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.